Home Inherited Disease and Carrier Screening Wilson Disease Genetic Test: ATP7B Gene Mutations, Copper, and Results

Wilson Disease Genetic Test: ATP7B Gene Mutations, Copper, and Results

By
Vita Library
-
3
Understand Wilson disease ATP7B genetic testing and copper results, including ceruloplasmin, urine and liver copper, two variants, carrier findings, VUS, and family risk.

A Wilson disease genetic test searches ATP7B for variants that impair the body’s ability to move copper into bile and incorporate it normally into ceruloplasmin. The test can confirm a difficult diagnosis, identify presymptomatic relatives, and provide exact variants for reproductive testing. It cannot be interpreted in isolation. Wilson disease can present with liver injury, neurologic movement problems, psychiatric changes, hemolysis, or a mixture of findings, and no single copper measurement is perfectly sensitive or specific. Ceruloplasmin may be low for reasons unrelated to Wilson disease or may be normal in an affected person. Total serum copper can be low even while toxic copper accumulates in tissues. A 24-hour urine collection can be incomplete, and liver copper can vary between biopsy samples. The strongest diagnosis integrates symptoms, eye examination, liver studies, copper tests, and ATP7B results. Two disease-causing variants usually establish the inherited diagnosis; one variant, a VUS, or a negative test requires further interpretation rather than a simple positive-or-negative conclusion.

  • Wilson disease is usually caused by pathogenic variants in both copies of ATP7B.
  • Genetic testing complements ceruloplasmin, urinary copper, eye examination, and sometimes liver copper measurement.
  • Two pathogenic variants support the diagnosis, but phase and clinical fit still matter.
  • One detected variant generally indicates carrier status or an incomplete molecular result, not confirmed disease.
  • Early identification matters because presymptomatic treatment can prevent irreversible liver and neurologic injury.

Table of Contents

Why Wilson disease requires a combined diagnosis

Wilson disease is an inherited disorder of copper metabolism. Untreated copper accumulation can damage the liver, brain, cornea, blood cells, kidneys, bones, and other tissues. Presentation ranges from an incidental elevation of liver enzymes to cirrhosis, acute liver failure, tremor, dystonia, dysarthria, parkinsonism, personality change, depression, psychosis, or hemolytic anemia. Symptoms can begin in childhood or much later in adulthood, and relatives with the same ATP7B variants may present differently.

This variability creates two opposite diagnostic risks. A clinician may overlook Wilson disease because the person is older, has no Kayser-Fleischer rings, has a normal ceruloplasmin value, or appears to have another liver or psychiatric condition. Alternatively, a low ceruloplasmin or one ATP7B variant may be overinterpreted as definitive when another explanation is more likely.

The diagnostic evaluation commonly combines:

  • clinical history and examination;
  • liver enzymes, bilirubin, coagulation, blood count, and markers of hemolysis;
  • serum ceruloplasmin and total serum copper;
  • basal 24-hour urinary copper excretion;
  • slit-lamp examination for Kayser-Fleischer rings and sometimes sunflower cataract;
  • neurologic examination and brain MRI when indicated;
  • ATP7B sequencing and deletion/duplication analysis;
  • liver copper quantification in selected unresolved cases;
  • newer copper measures, such as exchangeable copper, where validated and available.

No one component always settles the question. A molecular result can be diagnostic when two clearly pathogenic variants are found, yet urgent clinical management should not be delayed while sequencing is pending in a person with acute liver failure or strongly suspected symptomatic disease. Conversely, biochemical abnormalities should be rechecked and interpreted in context when the phenotype and genetics do not agree.

Wilson disease is treatable, but established neurologic injury or advanced liver damage may not fully reverse. Testing therefore has a preventive role: it can identify an apparently well sibling before organ injury develops. That makes family evaluation as important as confirming the first affected person.

How ATP7B disruption changes copper handling

ATP7B encodes a copper-transporting P-type ATPase expressed mainly in liver cells. Under normal conditions, ATP7B helps place copper into apoceruloplasmin and moves excess copper toward the bile canalicular system for excretion. Bile is the body’s major route for eliminating copper.

When both ATP7B copies have disease-causing variants, copper export into bile is impaired. Copper initially accumulates in the liver. As storage capacity is exceeded and hepatocytes are injured, loosely bound copper can circulate and deposit in the brain and other organs. This explains why a person can have systemic copper toxicity even when the routinely measured total serum copper is not elevated.

Ceruloplasmin adds another layer. Most copper in ordinary serum measurements is carried by ceruloplasmin. ATP7B dysfunction can impair incorporation of copper into apoceruloplasmin, and the unstable protein is degraded, lowering measured ceruloplasmin. As a result, total serum copper may be low because ceruloplasmin-bound copper is low, while the smaller non-ceruloplasmin-bound fraction is disproportionately high and toxic.

Wilson disease is a spectrum rather than a single laboratory pattern. Some ATP7B variants leave residual function. Age, modifier genes, diet, liver reserve, treatment, inflammation, hormones, and other factors influence biochemical values and presentation. Genotype-phenotype correlations are limited; a variant associated with neurologic disease in one family cannot reliably forecast the presentation in another person.

A carrier with one pathogenic ATP7B variant usually does not develop Wilson disease because the other copy provides sufficient function. Some carriers may have mildly altered copper or ceruloplasmin measurements, which can complicate screening. Carrier biochemistry should not be confused with the progressive copper accumulation that defines biallelic disease.

The autosomal recessive mechanism also means a family history can be absent. Parents are often healthy carriers, and affected siblings may differ in symptoms. Consanguinity, a known affected relative, unexplained childhood or young-adult liver disease, or a family pattern of neurologic and hepatic findings should raise suspicion, but none is required.

How to read copper and ceruloplasmin tests

Copper studies are most useful as a pattern, with attention to collection quality, treatment status, inflammation, and liver function.

Serum ceruloplasmin is often low in Wilson disease, but it is not a stand-alone test. Levels can also be low in severe liver failure, malnutrition, protein-losing conditions, aceruloplasminemia, Menkes-related disorders, and some unaffected carriers. Ceruloplasmin can rise as an acute-phase reactant and with estrogen exposure, pregnancy, inflammation, or infection, potentially masking a low baseline. Immunologic assays may measure both copper-bound and copper-free ceruloplasmin, so method-specific interpretation matters.

Total serum copper is commonly low in untreated Wilson disease because most circulating copper is ceruloplasmin-bound. It may become high during acute liver failure or marked hepatocellular injury when copper is released into plasma. A low value therefore does not mean the body lacks copper, and a high value does not by itself distinguish Wilson disease from other causes of liver injury.

Non-ceruloplasmin-bound copper is sometimes calculated from total copper and ceruloplasmin, but the result can be unreliable when either assay is imprecise. Negative calculated values are a sign of methodological limitations, not a biological absence of copper. Direct measures of exchangeable copper or relative exchangeable copper may improve diagnosis and monitoring in centers where they are standardized.

Basal 24-hour urinary copper reflects copper excretion through the kidneys. It is often elevated in symptomatic untreated disease and can help identify presymptomatic cases. Accurate collection is critical: every void during the timed period must be included, the container must be appropriate for trace-metal testing, and contamination must be avoided. Other liver diseases, cholestasis, acute hepatitis, and copper exposure can also raise urinary copper. Chelating treatment intentionally increases urine copper, so monitoring targets differ from diagnostic thresholds.

Hepatic copper concentration from liver biopsy can support the diagnosis when other evidence is inconclusive. Copper distribution may be patchy, especially with cirrhosis, so a small sample can underestimate the burden. Cholestatic disorders can increase liver copper without ATP7B disease. Biopsy also provides histology for other liver diagnoses, but it is invasive and is not required when clinical, biochemical, and molecular evidence is already convincing.

Kayser-Fleischer rings result from copper deposition in Descemet membrane of the cornea. They are common in neurologic Wilson disease but may be absent in liver-only or presymptomatic disease. Examination should be performed by an experienced eye professional using a slit lamp. Their absence does not exclude Wilson disease.

What ATP7B genetic testing can detect

Clinical ATP7B testing usually begins with sequence analysis and should be paired with deletion/duplication analysis if sequencing does not identify two explanatory variants.

Sequence analysis detects many missense, nonsense, frameshift, and canonical splice variants, as well as small insertions and deletions. ATP7B contains numerous rare variants, and many affected people are compound heterozygotes with a different finding on each chromosome.

Deletion and duplication analysis detects exon-level or larger copy-number changes that routine sequence analysis may miss. These account for a minority of cases but are important when only one pathogenic sequence variant has been found.

Targeted testing is appropriate when the exact familial variants are known. Testing only a common regional or ancestry-associated variant is not adequate for a general diagnostic evaluation because ATP7B variant diversity is broad.

Broader panels, exome, or genome sequencing may be useful when Wilson disease is one of several possible explanations for liver disease, movement disorder, or metabolic findings. The analysis should confirm adequate ATP7B coverage and copy-number sensitivity. Genome sequencing can examine deeper intronic and structural regions, but interpretation and validation remain laboratory-dependent.

RNA studies may help determine whether an intronic or synonymous variant alters splicing. Functional assays and ATP7B protein or peptide measurements are emerging adjuncts for unresolved cases, but access and clinical validation vary. Research evidence should be translated into a clinical report before it is used for family or reproductive decisions.

The laboratory should report the exact variant nomenclature, transcript, zygosity, classification, method, coverage limitations, and whether phase was established. For an autosomal recessive diagnosis, two variants should be in trans, meaning one affects each ATP7B copy. Testing parents can establish phase and confirm that two findings were inherited from opposite sides of the family.

A single-gene genetic test is most informative when the clinician supplies the phenotype and copper data. A laboratory may classify the same rare missense variant differently as new functional, population, or family evidence develops. Keeping the original report enables later reinterpretation.

Interpreting two-variant, one-variant, VUS, and negative results

The number of listed ATP7B variants is not enough. Classification and phase determine what the result means.

Two pathogenic or likely pathogenic variants in trans. This is a diagnostic molecular result for Wilson disease when the findings affect opposite gene copies. It can confirm symptomatic disease or identify a presymptomatic affected relative. Clinical evaluation remains necessary to determine current organ involvement and establish treatment and monitoring.

One pathogenic variant. In an unaffected person with normal evaluation, this usually indicates carrier status. In a person with convincing Wilson disease, it is an incomplete molecular result: a second variant may have been missed by the assay, lie in a noncoding region, be a deletion not assessed, or remain unclassified. One variant plus abnormal copper studies should prompt review rather than an automatic carrier-only conclusion.

One pathogenic variant plus one VUS. This pattern may or may not explain disease. The VUS requires evidence from phase, family segregation, population frequency, computational analysis, RNA studies, functional data, and biochemical fit. A variant of uncertain significance should not be treated as definitively disease-causing for predictive or reproductive testing.

Two VUS. Two uncertain findings do not become diagnostic simply because Wilson disease is recessive. They may be in cis, may be benign, or may not impair ATP7B enough to cause disease. Clinical and biochemical criteria determine management while the variants remain unresolved.

No pathogenic variant detected. A negative test reduces but does not eliminate the possibility of Wilson disease. The result is more reassuring after high-quality sequencing, copy-number analysis, and review for intronic or structural variants than after a limited panel. When the clinical and copper evidence is strong, treatment and further evaluation should not be abandoned because of negative genetics.

A single low-penetrance or debated variant. ATP7B contains changes whose contribution may depend on other variants or haplotypes. Interpretation should rely on a specialist clinical laboratory and current curated evidence rather than consumer databases or raw sequencing files.

Unexpected biallelic result in an asymptomatic person. This finding requires prompt hepatology or metabolic evaluation. Normal liver enzymes on one date do not prove that treatment is unnecessary. Presymptomatic disease is precisely the stage at which intervention may prevent organ damage.

Carriers should not be labeled as having Wilson disease based only on one pathogenic variant or a mildly low ceruloplasmin. However, a carrier with symptoms still deserves an ordinary medical evaluation; the result should not be used to dismiss unrelated liver, neurologic, or psychiatric disease.

Combining genetic, biochemical, and clinical evidence

Clinicians often use the Leipzig scoring system or a similar structured approach to combine Kayser-Fleischer rings, neurologic features, ceruloplasmin, hemolysis, urinary copper, hepatic copper, and ATP7B results. The score is a framework, not a substitute for specialist judgment. Test methods, age, acute liver failure, treatment status, and access to newer biomarkers can alter interpretation.

Several common patterns illustrate the need for integration.

Child with unexplained hepatitis, low ceruloplasmin, elevated urine copper, and two pathogenic ATP7B variants. The findings align and establish Wilson disease. Baseline liver and neurologic assessment and treatment should proceed.

Adult with tremor, dysarthria, Kayser-Fleischer rings, high urinary copper, and one pathogenic ATP7B variant. Wilson disease may still be highly likely. The next steps include comprehensive deletion/duplication and intronic review, phase analysis if another variant is found, and specialist treatment decisions based on the whole picture.

Healthy person with one pathogenic variant and mildly low ceruloplasmin. Carrier status is more likely than disease, especially if urine copper and clinical evaluation are normal. Testing for a second variant may be considered when values are persistently abnormal or family history is strong.

Person with cholestatic liver disease, high hepatic copper, normal ceruloplasmin, and negative ATP7B testing. Secondary copper accumulation may be more likely. The liver diagnosis and biopsy context need reassessment rather than assuming Wilson disease from tissue copper alone.

Acute liver failure with hemolysis and a Wilson-compatible biochemical pattern. This is an emergency. Genetic testing can confirm the cause and help the family, but care should follow acute liver failure protocols without waiting for molecular turnaround.

A diagnosis should also account for competing explanations. Autoimmune hepatitis, viral or drug-induced liver injury, metabolic fatty liver disease, other inherited cholestatic or copper disorders, and several movement or psychiatric disorders can overlap. Conversely, Wilson disease can coexist with another condition.

The most reliable conclusion is often written as a synthesis: “Wilson disease confirmed,” “highly likely while molecular testing remains incomplete,” “carrier only,” “biochemical findings indeterminate,” or “alternative diagnosis favored.” This is more useful than treating every individual result as independently positive or negative.

Family screening, carrier results, and reproductive risk

Wilson disease follows autosomal recessive inheritance. When both parents are carriers, each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier, and a 25% chance of producing a child who inherited neither familial variant.

Once an affected person’s two ATP7B variants are known, first-degree relatives should be evaluated promptly. Siblings have the highest immediate concern because an apparently healthy sibling may also have biallelic disease and can benefit from presymptomatic treatment. Targeted genetic testing for both familial variants is efficient, but clinical and biochemical assessment may be needed while results are pending or when the family genotype is incomplete.

Parents are expected to carry one variant each unless a de novo event, uniparental inheritance, nonparentage, or another unusual mechanism is present. Children of an affected person inherit one of that parent’s pathogenic variants and are usually obligate carriers if the other genetic parent is not a carrier. Because ATP7B carriers are not extremely rare, testing the reproductive partner can clarify the chance of an affected child.

If an affected person has children with a confirmed carrier, each pregnancy has a 50% chance of Wilson disease and a 50% chance of carrier status. If both partners are carriers but neither is affected, the usual 25% affected risk applies. Exact risk calculations require the confirmed familial variants and reliable partner testing.

Relatives should receive the full report, not a verbal statement that “the copper gene is in the family.” A targeted test must distinguish the two familial variants and interpret whether a relative inherited none, one, or both. If the index patient has one pathogenic variant and one VUS, predictive testing is less definitive and may need biochemical assessment.

Prenatal diagnosis using chorionic villus sampling or amniocentesis and preimplantation genetic testing for monogenic disease are possible when the familial variants are known. Decisions are personal and should include the fact that Wilson disease is treatable but requires lifelong adherence and monitoring. Carrier screening results should be reviewed with a genetics professional when one partner has Wilson disease or a known ATP7B variant.

How results change treatment and follow-up

A confirmed or strongly suspected diagnosis requires specialist-directed treatment to reduce toxic copper and prevent reaccumulation. Options include copper-chelating medicines, zinc salts that reduce intestinal copper absorption, and liver transplantation for selected patients with acute or advanced liver failure. Choice, dosing, sequence, and monitoring depend on hepatic versus neurologic presentation, age, pregnancy, adverse effects, and local guidelines.

Treatment is generally lifelong. Stopping therapy can cause rapid and severe deterioration, including liver failure. Genetic confirmation can improve adherence by resolving diagnostic uncertainty, but laboratory monitoring remains necessary because the variant does not show whether copper balance is currently controlled.

Follow-up may include liver tests, blood counts, urinalysis, serum and urinary copper measures, ceruloplasmin, neurologic assessment, medication adverse-effect surveillance, and evaluation of adherence. Interpretation differs by treatment: urinary copper can rise during chelation because copper is being mobilized and excreted, while goals during zinc therapy are different. Patients should use the targets supplied by their treatment center rather than diagnostic cutoffs found online.

Neurologic symptoms can transiently worsen after some treatment changes, so therapy should be initiated and adjusted by clinicians experienced in Wilson disease. Dietary advice is usually individualized and is not a substitute for medication. Avoiding very high-copper foods may be emphasized early in treatment, but overly restrictive diets can impair nutrition.

Pregnancy requires coordinated hepatology, obstetric, and genetics care. Treatment is usually continued with individualized adjustment because stopping it is dangerous. Medication decisions should be made before conception when possible and never changed solely from a genetic report.

For a presymptomatic relative with two pathogenic variants, normal examination does not mean “carrier.” The person has Wilson disease at a preclinical stage and generally needs treatment and surveillance. For a true carrier with one variant, disease-specific treatment is not indicated, but the result should be documented for family planning.

Revisit the molecular evaluation when only one variant was found, when two findings are unphased, when a VUS remains central to the diagnosis, or when older testing omitted copy-number and noncoding analysis. A well-integrated genetic diagnostic result can prevent both undertreatment of affected relatives and unnecessary treatment of carriers. In Wilson disease, the goal is not merely to name ATP7B variants—it is to identify who is accumulating copper early enough to protect the liver and brain.

References

Disclaimer

This article provides general education about ATP7B and copper testing and is not a substitute for evaluation by a hepatologist, neurologist, metabolic specialist, or genetic counselor. Suspected Wilson-related acute liver failure, hemolysis, rapidly progressive neurologic symptoms, or severe psychiatric change requires urgent medical care. Do not start, stop, or adjust chelation, zinc, dietary restrictions, or pregnancy treatment based only on this article or an isolated laboratory value.

RELATED ARTICLESMORE FROM AUTHOR